PROC
ENSG00000115718
Target class
Enzyme
Chromosome
2
Approved drugs
1
Clinical candidates (approved and in development)
2
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Target name
- PROC
- Gene name
- Protein C, inactivator of coagulation factors Va and VIIIa
- Gene symbol
- PROC
- Protein name
- Vitamin K-dependent protein C (EC 3.4.21.69) (Anticoagulant protein C) (Autoprothrombin IIA) (Blood coagulation factor XIV) [Cleaved into: Vitamin K-dependent protein C light chain; Vitamin K-dependent protein C heavy chain; Activation peptide]
- Gene biotype
- Protein coding
- Gene family
- Receptor ligands|Gla domain containing
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 4
- Highest tissue expression
- 241.55
- Tissue specificity (Gini)
- 0.932
- Tissue specificity (tau)
- 0.998
- KEGG gene identifiers
- hsa:5624
- Protein interaction confidence
- 0.851088
- Protein interaction partners
- 34
- R-HSA-159740
- R-HSA-159763
- R-HSA-159782
- R-HSA-202733
- R-HSA-381426
- R-HSA-8957275
- R-HSA-9769733
- R-HSA-9769739
- R-HSA-9769743
- R-HSA-9930449
- R-HSA-9930479
- End position
- 127429762
- Start position
- 127415933
- Chromosome
- 2
- Strand
- Forward
- Secreted . Golgi apparatus . Endoplasmic reticulum .
- PubMed 25618265
- PubMed 22531345
- PubMed 25748729
- Tissue specificity (tau)
- 0.997554
- Expression inequality (Gini)
- 0.932319
Expression in transcripts per million
- Liver
- 241.55
- Kidney - Cortex
- 7.24
- Kidney - Medulla
- 6.35
- Stomach
- 1.91
- Brain - Hypothalamus
- 0.85
Expression in transcripts per million
- Liver241.55
- Kidney - Cortex7.24
- Kidney - Medulla6.35
- Stomach1.91
- Brain - Hypothalamus0.85
- Small Intestine - Terminal Ileum0.64
- Brain - Nucleus accumbens (basal ganglia)0.62
- Artery - Tibial0.57
- Colon - Transverse0.55
- Brain - Amygdala0.53
- Brain - Frontal Cortex (BA9)0.46
- Bladder0.45
- Brain - Anterior cingulate cortex (BA24)0.43
- Artery - Coronary0.43
- Brain - Hippocampus0.43
- Artery - Aorta0.42
- Brain - Cortex0.42
- Pituitary0.41
- Brain - Caudate (basal ganglia)0.41
- Fallopian Tube0.4
- Brain - Substantia nigra0.37
- Whole Blood0.36
- Prostate0.35
- Brain - Cerebellum0.35
- Thyroid0.35
And 29 more, listed on the interactive page.
- GO:0030195
- GO:0043066
- GO:0050728
- GO:0050819
- GO:1903142
- GO:0005576
- GO:0005783
- GO:0005788
- GO:0005794
- GO:0005796
- GO:0004252
- GO:0005515
Related records
Trials (535)
- A Clinical Study of Intravenous Immunoglobulin
- A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy
- A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers
- A Comparison of TCC-EZ Using Human Amnion Allograft vs TCC-EZ and Standard Wound Care in Treating Diabetic Foot Ulcers.
- A Controlled Study to Evaluate the Safety and Immunogenicity of StreptAnova™ in Healthy Adults
- A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion
- A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors
- A Novel Faecal Microbiota Transplantation System for Treatment of Primary and Recurrent Clostridium Difficile Infection
- A Novel Therapeutic Treatment of Pyoderma Gangrenosum
- A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency
- A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
- A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents
- A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant
- A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
- A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected Children
- A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy
- A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
- A Phase Ⅲ Clinical Study of SNA02-48 Injection
- A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)
- A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)
Drugs (2)
- Protein C concentrate (human) Vitamin K-dependent protein C exogenous protein
- Prothrombin complex concentrate Vitamin K-dependent protein C exogenous protein